Physician profile
David O Mccrary
NPI 1821034745
$3,152.12
in general payments reported to CMS, 2019-2025
36 companies · $585 in 2025
The $585 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,503 · 2020: $221 · 2021: $17.92 · 2022: $65.39 · 2023: $356 · 2024: $405 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,345.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $482.56 | 2019-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $385.06 | 2019-2025 | Zerbaxa, Delstrigo, Dificid |
| Novo Nordisk INC | $264.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $249.63 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $225.57 | 2024-2025 | Vowst |
| Tetraphase Pharmaceuticals, INC. | $185.42 | 2019 | |
| Amgen INC. | $149.06 | 2019-2025 | Repatha, Otezla |
| Pfizer INC. | $147.36 | 2019-2023 | |
| Abbott Laboratories | $142.58 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $98.88 | 2019 | |
| Insmed, INC. | $81.04 | 2025 | Arikayce |
| Nestle Healthcare Nutrition INC. | $66.63 | 2023 | |
| Cumberland Pharmaceuticals, INC. | $62.18 | 2019-2020 | |
| Lilly USA, LLC | $56.48 | 2025 | Zepbound, Mounjaro |
| Allergan, INC. | $51.03 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $48.04 | 2023-2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $44.29 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $37.66 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $31.86 | 2019 | |
| Janssen Pharmaceuticals, INC | $30.16 | 2019 | |
| Sanofi Pasteur INC. | $28.96 | 2019 | |
| Melinta Therapeutics, LLC | $28.60 | 2019 | |
| Glaxosmithkline, LLC. | $28.59 | 2019-2020 | |
| Neotract INC. | $24.98 | 2019 | |
| Sumitomo Pharma America, INC. | $22.18 | 2023 | Gemtesa |
| Axsome Therapeutics, INC. | $21.83 | 2024 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.46 | 2019 | |
| Genentech USA, INC. | $19.24 | 2019 | |
| Vanda Pharmaceuticals INC. | $17.98 | 2020 | |
| Abbvie INC. | $17.92 | 2021 | |
| Viiv Healthcare Company | $15.57 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.27 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.85 | 2019 | |
| Shionogi INC | $13.20 | 2022 | |
| Nabriva Therapeutics, Plc | $12.15 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mccrary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.